Lung Cancer
Conference Coverage
Lung cancer screening pushes 20-year survival rate to 80%
Less than 6% of high-risk smokers get the recommended annual lung cancer screening.
News
Durvalumab combinations show tentative promise in NSCLC
Phase 2 study indicates improved survival and objective response rate when combined with other immunotherapies.
Opinion
Had my patient come in today, we may have had other options
FDA’s approval of trastuzumab deruxtecan is a game-changer for NSCLC patients with HER alterations.
News
Despite benefits, extended-interval pembro uptake remains low
It’s possible that low uptake could stem from clinicians’ doubts about switching to an extended-interval dose, given that the FDA’s approval was...
Conference Coverage
Weight gain linked to cancer survival in men and women
The finding underscores the need for nutritional support emphasized in 2020 ASCO guidelines.
Latest News
Atezolizumab doubles survival of NSCLC patients with poor performance status
Patients typically excluded from clinical trials because of age or comorbidities had better survival with atezolizumab than single-agent...
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
News
Opioids after lung cancer surgery may up all-cause mortality risk
“New long-term opioid use may be associated with poor long-term survival outcomes, especially in potent opioid users.”
Conference Coverage
In NSCLC, not all EGFR mutations are the same
Patients with the Ex20 insertion may buck trend by responding well to ICIs.
